Eagle Pharmaceuticals Stock Price, News & Analysis (NASDAQ:EGRX)

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) announced its earnings results on Thursday, August, 8th. The specialty pharmaceutical company reported $0.48 earnings per share for the quarter, beating analysts' consensus estimates of $0.31 by $0.17. The specialty pharmaceutical company had revenue of $56.70 million for the quarter, compared to the consensus estimate of $53.61 million. Eagle Pharmaceuticals had a net margin of 19.79% and a return on equity of 24.10%. Eagle Pharmaceuticals's quarterly revenue was down 4.4% on a year-over-year basis. During the same period last year, the firm posted $0.99 earnings per share. View Eagle Pharmaceuticals' Earnings History.

Eagle Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Eagle Pharmaceuticals.

4 equities research analysts have issued 1-year price targets for Eagle Pharmaceuticals' shares. Their predictions range from $50.00 to $66.00. On average, they expect Eagle Pharmaceuticals' stock price to reach $57.00 in the next twelve months. This suggests that the stock has a possible downside of 7.6%. View Analyst Price Targets for Eagle Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Eagle Pharmaceuticals.

News articles about EGRX stock have trended somewhat negative recently, InfoTrie reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Eagle Pharmaceuticals earned a news sentiment score of -1.5 on InfoTrie's scale. They also gave media headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Eagle Pharmaceuticals.

Eagle Pharmaceuticals saw a drop in short interest during the month of September. As of September 30th, there was short interest totalling 1,730,000 shares, a drop of 9.9% from the August 30th total of 1,920,000 shares. Based on an average daily trading volume, of 150,800 shares, the days-to-cover ratio is currently 11.5 days. Approximately 13.2% of the shares of the company are short sold. View Eagle Pharmaceuticals' Current Options Chain.

Some companies that are related to Eagle Pharmaceuticals include Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY), Allakos (ALLK), Nektar Therapeutics (NKTR), Taro Pharmaceutical Industries (TARO), Global Blood Therapeutics (GBT), Emergent Biosolutions (EBS), Alkermes (ALKS), Genmab A/S (GMAB), HUTCHISON CHINA/S (HCM), Myokardia (MYOK), Ultragenyx Pharmaceutical (RARE), Arena Pharmaceuticals (ARNA), Biohaven Pharmaceutical (BHVN) and PTC Therapeutics (PTCT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Exelixis (EXEL), Gilead Sciences (GILD), Teekay Tankers (TNK), Celgene (CELG), GW Pharmaceuticals PLC- (GWPH), Intercept Pharmaceuticals (ICPT), Synergy Pharmaceuticals (SGYP), Radius Health (RDUS), bluebird bio (BLUE) and Clovis Oncology (CLVS).

Eagle Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Smith Graham & Co. Investment Advisors LP (1.13%), Scout Investments Inc. (0.67%), Envestnet Asset Management Inc. (0.08%), State of Alaska Department of Revenue (0.06%), Robeco Institutional Asset Management B.V. (0.05%) and Pacer Advisors Inc. (0.05%). Company insiders that own Eagle Pharmaceuticals stock include Douglas L Braunstein, Hudson Executive Capital Lp, Sander A Flaum and Scott Tarriff. View Institutional Ownership Trends for Eagle Pharmaceuticals.

EGRX stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc.. Company insiders that have sold Eagle Pharmaceuticals company stock in the last year include Douglas L Braunstein, Hudson Executive Capital Lp and Scott Tarriff. View Insider Buying and Selling for Eagle Pharmaceuticals.

EGRX stock was purchased by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., State of Alaska Department of Revenue, Envestnet Asset Management Inc., Pacer Advisors Inc. and Smith Graham & Co. Investment Advisors LP. View Insider Buying and Selling for Eagle Pharmaceuticals.

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EGRX stock can currently be purchased for approximately $61.71.

Eagle Pharmaceuticals has a market capitalization of $843.58 million and generates $213.31 million in revenue each year. The specialty pharmaceutical company earns $31.90 million in net income (profit) each year or $2.09 on an earnings per share basis. Eagle Pharmaceuticals employs 96 workers across the globe.View Additional Information About Eagle Pharmaceuticals.

The official website for Eagle Pharmaceuticals is http://www.eagleus.com/.

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]